Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-PCSSC dose-ranging in high cardiovascular risk subjects with elevated LDL-C
2015-003772-74Phase 2Completed
- Sponsor
- The Medicines Company
- Start
- Oct 2015
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia and cardiac morbidity comparing ALN-PCSSC with Placebo (2 arms). Primary endpoint: Percentage change in LDL-C from baseline to Day 180. Started Oct 2015; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on 2015-003772-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003772-74.